The latest news on next-generation sequencing.
The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.
The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant to treat certain PIK3CA-mutated breast cancers.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
CUTseq uses enzyme-based fragmentation and in vitro transcription to barcode DNA, saving money when preparing 1,000 samples or more.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
Clonal hematopoiesis variants appear to outnumber tumor mutations in the plasma of most cancer patients, the investigators found in their study.
Clinical genomics is just one business area for PHIX, which also intends to sell genomic tools and introduce a variety of agriculture and lifestyle-focused tests.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
The trial aims to combine personal information, pharmacogenomics data, and machine-learning tools to select the best anti-seizure medication for patients.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.